Recent Advances on Innovative Radiopharmaceuticals in Preclinical and Clinical Cancer Research
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 644
Special Issue Editors
Interests: cancer nuclear medicine for diagnosis and therapeutics
Special Issue Information
Dear Colleagues,
Recently, nuclear medicine has gained a crucial role in cancer characterization, staging, restaging and follow-up, either for solid tumors or oncohematologic ones. Moreover, very recently, the field of interest for nuclear medicine been has further extended to include cancer therapy too, mainly peptide receptor radionuclide therapy (PRRT).
We are pleased to invite you to submit your contributions dedicated to advances in cancer preclinical and clinical nuclear medicine, focusing either on new diagnostic molecules and procedures or recent therapeutic applications.
This Special Issue aims to investigate the use of innovative radiopharmaceuticals and novel technological applications in the field of positron emission tomography (PET) diagnostic imaging, such as PET/computed tomography (CT), PET/magnetic resonance imaging (MRI), and molecular radiotherapy in oncology. The invited contributions should improve knowledge regarding the in vivo characterization of cancer biological processes, forming the basis for the predictive and prognostic role of molecular imaging and allowing for more personalized treatments based on specific molecular targeting.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) preclinical research and clinical trials on new cancer radiopharmaceuticals.
We look forward to receiving your contributions.
Dr. Désirée Déandréis
Dr. Roberto Passera
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nuclear medicine
- radiopharmaceutical
- PET-CT
- clinical trial
- preclinical trial
- cancer
- clinical oncology
- solid tumors
- oncohematology
- PRRT
- urologic oncology
